Q3 2023 · 13F-HR
Kynam Capital Management, LPholdings as filed
Filed 2023-11-14 · accession 0001085146-23-004352
$611.4M
Reported value
30
Positions
2023-09-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 632307104 | NTRA | NATERA INC | $132.9M | 21.7% | 3,003,668 | Common | SOLE |
| 15117B202 | CLDX | CELLDEX THERAPEUTICS INC NEW | $88.1M | 14.4% | 3,200,000 | Common | SOLE |
| 92243G108 | PCVX | VAXCYTE INC | $66.4M | 10.9% | 1,302,407 | Common | SOLE |
| 87164F105 | SNDX | SYNDAX PHARMACEUTICALS INC | $52.3M | 8.55% | 3,600,000 | Common | SOLE |
| 92337R101 | VERA | VERA THERAPEUTICS INC | $40.5M | 6.63% | 2,956,053 | Common | SOLE |
| 74366E102 | PTGX | PROTAGONIST THERAPEUTICS INC | $30.3M | 4.96% | 1,818,657 | Common | SOLE |
| 901384107 | TSVT* | 2SEVENTY BIO INC | $23.3M | 3.82% | 5,953,825 | Common | SOLE |
| Y95308105 | WVE | WAVE LIFE SCIENCES LTD | $22.6M | 3.70% | 3,932,082 | Common | SOLE |
| 09058V103 | BCRX | BIOCRYST PHARMACEUTICALS INC | $22.2M | 3.63% | 3,133,193 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $21.5M | 3.52% | 2,210,125 | Common | SOLE |
| 53635D202 | LQDA | LIQUIDIA CORPORATION | $12.7M | 2.07% | 2,000,000 | Common | SOLE |
| 00445A100 | — | ACELYRIN INC | $12.2M | 2.00% | 1,200,000 | Common | SOLE |
| 023111206 | — | AMARIN CORP PLC | $11.1M | 1.81% | 12,022,957 | Common | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $10.7M | 1.76% | 699,681 | Common | SOLE |
| 877619106 | TSHA | TAYSHA GENE THERAPIES INC | $10.4M | 1.70% | 3,281,313 | Common | SOLE |
| 89422G107 | TVTX | TRAVERE THERAPEUTICS INC | $8.6M | 1.40% | 957,502 | Common | SOLE |
| 12233L107 | BNR | BURNING ROCK BIOTECH LTD | $8.2M | 1.35% | 8,500,000 | Common | SOLE |
| 268158201 | DVAX | DYNAVAX TECHNOLOGIES CORP | $7.4M | 1.21% | 500,000 | Common | SOLE |
| 87164F105 | SNDX | SYNDAX PHARMACEUTICALS INC | $5.8M | 0.95% | 400,000 | CALL | SOLE |
| 869367102 | — | SUTRO BIOPHARMA INC | $5.4M | 0.88% | 1,552,675 | Common | SOLE |
| 142038108 | CRBU | CARIBOU BIOSCIENCES INC | $5.1M | 0.84% | 1,068,527 | Common | SOLE |
| 152309100 | CNTA | CENTESSA PHARMACEUTICALS PLC | $4.7M | 0.77% | 730,472 | Common | SOLE |
| 45258J102 | IMVT | IMMUNOVANT INC | $3.8M | 0.63% | 100,000 | PUT | SOLE |
| 68062P106 | OLMA | OLEMA PHARMACEUTICALS INC | $2.9M | 0.48% | 235,176 | Common | SOLE |
| 74587V107 | PBYI | PUMA BIOTECHNOLOGY INC | $1.2M | 0.20% | 473,975 | Common | SOLE |
| 207523101 | — | CONNECT BIOPHARMA HLDGS LTD | $434,003 | 0.07% | 535,005 | Common | SOLE |
| 38341P102 | GOSS | GOSSAMER BIO INC | $208,200 | 0.03% | 250,000 | Common | SOLE |
| 89422G107 | TVTX | TRAVERE THERAPEUTICS INC | $134,994 | 0.02% | 15,100 | CALL | SOLE |
| 64049K203 | — | NEOLEUKIN THERAPEUTICS INC | $94,946 | 0.02% | 24,037 | Common | SOLE |
| 14888D208 | — | CATALYST BIOSCIENCES INC | $43,435 | 0.01% | 90,058 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.